The Tn antigen is a well-known tumor-associated carbohydrate determinant, often incorporated in glycopeptides to develop cancer vaccines. Herein, four copies of a conformationally constrained mimetic of the antigen TnThr (GalNAc-Thr) were conjugated to the adjuvant CRM197, a protein licensed for human use. The resulting vaccine candidate, mime[4]CRM elicited a robust immune response in a triple-negative breast cancer mouse model, correlated with high frequency of CD4+ T cells and low frequency of M2-type macrophages, which reduces tumor progression and lung metastasis growth. Mime[4]CRM-mediated activation of human dendritic cells is reported, and the proliferation of mime[4]CRM-specific T cells, in cancer tissue and peripheral blood of patients with breast cancer, is demonstrated. The locked conformation of the TnThr mimetic and a proper presentation on the surface of CRM197 may explain the binding of the conjugate to the anti-Tn antibody Tn218 and its efficacy to fight cancer cells in mice.
A Structurally Simple Vaccine Candidate Reduces Progression and Dissemination of Triple-Negative Breast Cancer / Amedei, A.; Asadzadeh, F.; Papi, F.; Vannucchi, M. G.; Ferrucci, V.; Bermejo, I. A.; Fragai, M.; De Almeida, C. V.; Cerofolini, L.; Giuntini, S.; Bombaci, M.; Pesce, E.; Niccolai, E.; Natali, F.; Guarini, E.; Gabel, F.; Traini, C.; Catarinicchia, S.; Ricci, F.; Orzalesi, L.; Berti, F.; Corzana, F.; Zollo, M.; Grifantini, R.; Nativi, C.. - In: ISCIENCE. - ISSN 2589-0042. - 23:6(2020), pp. 101250-101263. [10.1016/j.isci.2020.101250]
A Structurally Simple Vaccine Candidate Reduces Progression and Dissemination of Triple-Negative Breast Cancer
Asadzadeh F.Co-primo
Conceptualization
;Ferrucci V.Secondo
Data Curation
;Giuntini S.;Bombaci M.;Zollo M.
Co-ultimo
Writing – Original Draft Preparation
;Nativi C.
2020
Abstract
The Tn antigen is a well-known tumor-associated carbohydrate determinant, often incorporated in glycopeptides to develop cancer vaccines. Herein, four copies of a conformationally constrained mimetic of the antigen TnThr (GalNAc-Thr) were conjugated to the adjuvant CRM197, a protein licensed for human use. The resulting vaccine candidate, mime[4]CRM elicited a robust immune response in a triple-negative breast cancer mouse model, correlated with high frequency of CD4+ T cells and low frequency of M2-type macrophages, which reduces tumor progression and lung metastasis growth. Mime[4]CRM-mediated activation of human dendritic cells is reported, and the proliferation of mime[4]CRM-specific T cells, in cancer tissue and peripheral blood of patients with breast cancer, is demonstrated. The locked conformation of the TnThr mimetic and a proper presentation on the surface of CRM197 may explain the binding of the conjugate to the anti-Tn antibody Tn218 and its efficacy to fight cancer cells in mice.File | Dimensione | Formato | |
---|---|---|---|
A Structurally Simple Vaccine Candidate Reduces Progression and Dissemination of Triple-Negative Breast Cancer.pdf
accesso aperto
Descrizione: pdf
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
12.28 MB
Formato
Adobe PDF
|
12.28 MB | Adobe PDF | Visualizza/Apri |
AMEDEI ET AL.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
11.78 MB
Formato
Adobe PDF
|
11.78 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.